Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Heart

• Publication date

  2004-06-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/hrt.2003.017368PMID 15201246PMCID PMC1768327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Long QTc predicts future cardiac death in stroke survivors

  2003cited by this paper
• Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure.

  2002cited by this paper
• Endothelial function: a barometer for cardiovascular risk?

  2002cited by this paper
• Prognostic Value of Coronary Vascular Endothelial Dysfunction

  2002cited by this paper
• Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis

  2002cited by this paper
• Allopurinol and Endothelial Function in Heart Failure

  2002cited by this paper
• Allopurinol and endothelial function in heart failure: future or fantasy?

  2002cited by this paper
• Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.

  2002cited by this paper
• Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure

  2002cited by this paper
• Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.

  2002cited by this paper
• Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study

  2002cited by this paper
• Harrison's Advances in Cardiology

  2002cited by this paper
• Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.

  2001cited by this paper
• Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.

  2001cited by this paper
• Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure.

  2001cited by this paper
• Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients

  2001cited by this paper
• Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease

  2001cited by this paper
• Aldosterone Induces Angiotensin-Converting-Enzyme Gene Expression in Cultured Neonatal Rat Cardiocytes

  2001cited by this paper
• Serious adverse events experienced by patients with chronic heart failure taking spironolactone

  2001cited by this paper
• Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

  2000cited by this paper
• Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

  2000cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)

  2000cited by this paper
• Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.

  2000cited by this paper
• Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain.

  2000cited by this paper
• Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

  2000cited by this paper
• Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) levels improves outcome

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

  1999cited by this paper
• Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis.

  1999cited by this paper
• Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

  1998cited by this paper
• Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor.

  1998cited by this paper
• Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.

  1997cited by this paper
• Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

  1996cited by this paper
• Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

  1996cited by this paper
• Heart rate variability. Standards of measurement, physiological interpretation, and clinical use

  1996cited by this paper
• Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

  1996cited by this paper
• Measuring forearm blood flow and interpreting the responses to drugs and mediators.

  1995cited by this paper
• Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.

  1995cited by this paper
• Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure.

  1994cited by this paper
• Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.

  1993cited by this paper
• Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.

  1993cited by this paper
• Evaluation of the Reynolds Pathfinder II system for 24 h heart rate variability analysis.

  1991cited by this paper
• The Hospital Anxiety and Depression Scale.

  1987cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper

• Serum aminoterminal type III procollagen peptide reflects increased vascular thickness in healthy, young adults

  2026cites this paper
• Molecular Mechanisms and Therapeutic Implications of Endothelial Dysfunction in Patients with Heart Failure

  2023cites this paper
• Endothelial, Vascular and Sympathetic Alterations as Therapeutic Targets in Chronic Heart Failure

  2023cites this paper
• Leukocyte–endothelial interaction in CKD

  2023cites this paper
• Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists

  2022cites this paper
• The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study

  2022cites this paper
• A retrospective study on the short-term effect of high-dose spironolactone (80 mg/d) on chronic congestive heart failure

  2021cites this paper
• Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study.

  2021cites this paper
• Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases

  2021cites this paper
• Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease

  2020cites this paper
• Alterations in the Peripheral Circulation in Heart Failure

  2020cites this paper
• Therapeutic potential of spironolactone in ankylosing spondylitis patients: Relation to disease activity and functional status

  2020cites this paper
• Endothelial Dysfunction in Primary Aldosteronism

  2019cites this paper
• The Endothelial Mineralocorticoid Receptor: Contributions to Sex Differences in Cardiovascular Disease.

  2019cites this paper
• Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials

  2019cites this paper
• Neurohormonal Axis and Natriuretic Peptides in Heart Failure

  2018cites this paper
• Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?

  2018cites this paper
• Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-&kgr;B and AP-1 signalling

  2018cites this paper
• Insuffisance cardiaque : traitement médical

  2018cites this paper
• The Effect of Spironolactone on Cerebral Blood Flow and Cognition

  2018cites this paper
• The Effect of Treatments for Rheumatoid Arthritis on Endothelial Dysfunction Evaluated by Flow-Mediated Vasodilation in Patients with Rheumatoid Arthritis.

  2016cites this paper
• Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men

  2016cites this paper
• Cardiac rehabilitation improves coronary endothelial function in patients with heart failure due to dilated cardiomyopathy: A positron emission tomography study

  2016cites this paper
• Forearm Resistance-Vessel Dilatation Function During Reactive Hyperemia in Patients With Resistant Hypertension.

  2016cites this paper
• Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double‐Blind, Randomized, Placebo‐Controlled Trial

  2016cites this paper
• Avaliação da adição de espironolactona à terapia da Hipertensão Arterial Resistente em um ambulatório de referência.

  2016cites this paper
• Spironolactone for people aged 70 or over with osteoarthritic knee pain

  2016cites this paper
• Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.

  2015cites this paper
• Current and Future Strategies for the Diagnosis and Treatment of Cardiac Fibrosis

  2015cites this paper
• Spironolactone for People Age 70 Years and Older With Osteoarthritic Knee Pain: A Proof‐of‐Concept Trial

  2015cites this paper
• Heart Failure and Chronic Kidney Disease: Should We Use Spironolactone?

  2015influential citation
• Eplerenone in chronic heart failure with depressed systolic function.

  2015cites this paper
• Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure

  2015cites this paper
• Cardiac Fibrosis and Heart Failure: Cause or Effect?

  2015influential citation
• Effect of Aldosterone-Producing Adenoma on Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism

  2015cites this paper
• Modulation of the QT interval duration in hypertension with antihypertensive treatment

  2015cites this paper
• Effects of Add-on Therapy Consisting of a Selective Mineralocorticoid Receptor Blocker on Arterial Stiffness in Patients with Uncontrolled Hypertension.

  2015cites this paper
• Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms.

  2015cites this paper
• [Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage].

  2014cites this paper
• Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

  2014cites this paper
• Aldosterone Promotes Vascular Remodeling by Direct Effects on Smooth Muscle Cell Mineralocorticoid Receptors

  2014cites this paper
• Vad har Spironolakton för effekt på hjärta, kärl och det sympatiska nervsystemet hos hjärtsviktspatienter?

  2014cites this paper
• The cardioprotective effects of mineralocorticoid receptor antagonists.

  2014cites this paper
• Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms

  2014cites this paper
• Inflammation and chronic heart failure: from biomarkers to novel anti-inflammatory therapeutic strategies.

  2014cites this paper
• Mineralcorticoid antagonists in heart failure.

  2014cites this paper
• Efeitos do Bloqueio Precoce da Aldosterona na Estrutura e Função Cardíaca e na Composição da Matriz Colágena Miocárdica de Ratos Espontaneamente Hipertensos

  2013cites this paper
• Renin–Angiotensin–Aldosterone System Inhibitors in Heart Failure

  2013cites this paper
• Targeting the renin–angiotensin–aldosterone system in heart failure

  2013cites this paper
• Spironolactone improves endothelial dysfunction in ankylosing spondylitis

  2013cites this paper
• Systematic approach: an evidence management strategy for better decision‐making

  2013cites this paper
• Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation

  2013cites this paper
• A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial

  2013cites this paper
• Mineralocorticoid Receptor Antagonism and Aldosterone Synthesis Inhibition Do Not Improve Glomerulosclerosis and Renal Interstitial Fibrosis in a Model of Chronic Kidney Allograft Injury

  2012cites this paper
• Effects of interventions in the RAAS and sodium status on classical and non-classical outcome parameters in chronic kidney disease

  2012cites this paper
• Feline cardiomyopathy

  2012cites this paper
• Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho‐Associated Kinase Activity in Patients With Hypertension

  2012cites this paper
• Endothelial dysfunction, arterial stiffness, and heart failure.

  2012cites this paper
• Central regulation of blood pressure by the mineralocorticoid receptor.

  2012cites this paper
• Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.

  2012cites this paper
• Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.

  2012cites this paper
• Ethnic differences in endothelial function and monocyte subsets in heart failure

  2012cites this paper
• Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice.

  2012cites this paper
• Mineralocorticoid receptors in vascular function and disease.

  2012influential citation
• Endothelial function and the effects of aldosterone blockade

  2011cites this paper
• Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease.

  2011cites this paper
• Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.

  2011cites this paper
• Spironolactone Inhibits NADPH Oxidase-Induced Oxidative Stress and Enhances eNOS in Human Endothelial Cells

  2011cites this paper
• The regulation of cell growth and survival by aldosterone.

  2011cites this paper
• The Interplay of Cardiovascular Burden with Cognition and Mortality Tuomas Kerola The Interplay of Cardiovascular Burden with Cognition and Mortality

  2011cites this paper
• Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure

  2011cites this paper
• Physiology of aldosterone and pharmacology of aldosterone blockers

  2011cites this paper
• Treatment of chronic heart failure with aldosterone-blocking agents

  2011cites this paper
• Corticosteroid hormone action in the cardiovascular system

  2011cites this paper
• Vascular action of glycine in hypertensive rat models

  2011cites this paper
• Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?

  2011cites this paper
• Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF)

  2010cites this paper
• The Effects of Vitamin D Supplementation on Physical Function and Quality of Life in Older Patients With Heart Failure: A Randomized Controlled Trial

  2010cites this paper
• Aldosterone Induces Oxidative Stress Via NADPH Oxidase and Downregulates the Endothelial NO Synthesase in Human Endothelial Cells

  2010cites this paper
• Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure.

  2010cites this paper
• Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.

  2010cites this paper
• Should aldosterone blockade be used beyond current indications in heart failure?

  2009influential citation
• A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction

  2009cites this paper
• The clinical pharmacology of eplerenone

  2009cites this paper
• Rapid aldosterone signaling and vascular reactivity: relax or don't do it.

  2009cites this paper
• Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats.

  2009cites this paper
• Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis

  2009cites this paper
• The clinical pharmacology of eplerenone.

  2009cites this paper
• Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles

  2008cites this paper
• Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.

  2008cites this paper
• Advances in heart failure: natriuretic peptide testing.

  2008cites this paper
• Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure

  2008cites this paper
• The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction.

  2008cites this paper
• Prognostic threshold levels of NT-proBNP testing in primary care.

  2008cites this paper
• Natriuretic Peptide Testing in Primary Care

  2008influential citation
• Selective Mineralocorticoid Receptor Blocker Eplerenone Reduces Resistance Artery Stiffness in Hypertensive Patients

  2008cites this paper
• Intercellular Adhesion Molecule-1 Expression and Promote Leukocyte Adhesion Functional Mineralocorticoid Receptors in Human Vascular Endothelial Cells Regulate

  2008cites this paper
• Mineralocorticoid receptor antagonists and endothelial function.

  2008cites this paper
• Outpatient monitoring and treatment of chronic heart failure guided by amino-terminal pro-B-type natriuretic peptide measurement.

  2008cites this paper
• Rôles physiopathologiques des récepteurs corticostéroïdes dans le rein et dans l'endothélium vasculaire : apports des modèles conditionnels transgéniques

  2008cites this paper